Precigen, Inc.
Precigen, Inc. (PGEN) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · PGEN · as of Jun 8, 2026
Key Statistics
Explore Precigen, Inc. Data
pgen stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 16 · Buy rate: 68.8%
The PGEN analyst consensus is Buy, based on ratings from 16 Wall Street analysts over the past 3 months. The average 12-month price target is $14.00, representing +288.35% upside from the current price of $3.60.
Competitors & Peers
pgen competitorsPGEN
AMLX
DNTH
ELVN
IMTX
NKTRStock Performance
Full HistoryAbout Precigen, Inc.
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regener…
what is precigen, inc. · pgen stock overview · precigen, inc. company profile · who is precigen, inc. ceo · pgen NASDAQ · precigen, inc. headquarters · precigen, inc. business segments
About Stock Overview & Key Data
Precigen, Inc. (PGEN) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Aug 8, 2013. As of the latest trading session, PGEN stock price is $3.60, with a market capitalization of $1.1B. The stock has returned +136.33% over the past 12 months and -15.19% year-to-date.
According to 16 Wall Street analysts, the consensus rating for Precigen, Inc. stock is Buy, with an average 12-month price target of $14.00. In fiscal year 2025, Precigen, Inc. reported revenue of $9.7M and net income of -$250.6M. For detailed data — including Precigen, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Precigen, Inc. (PGEN) stock price is $3.60. The stock is traded on NASDAQ under the ticker symbol PGEN. The 52-week range is $1.30 – $5.47.